Datum Källa Rubrik Typ Alternativ
2023-07-10 Nanexa Sommarbrev från Nanexa Pressreleaser Ladda ner | Visa Stäng
2023-07-10 Nanexa Summer letter from Nanexa Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Nanexa Bulletin from Nanexa’s Annual General Meeting 2023 Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Nanexa Kommuniké från årsstämma i Nanexa Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Nanexa Nanexa har slutfört den planerade rekryteringen till Fas 1-studien av NEX-20 Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Nanexa Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20 Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Nanexa Nanexa skriver kontrakt med internationellt ledande CRO inom diabetes för fas I-studie med NEX-22 Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Nanexa Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22 Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Redeye Redeye: Nanexa - Moments of truth closing in Pressreleaser Ladda ner | Visa Stäng
2023-05-10 Nanexa Kallelse till årsstämma i Nanexa AB Pressreleaser Ladda ner | Visa Stäng
2023-05-10 Nanexa Notice of Annual General Meeting in Nanexa AB Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Emergers Emergers: Equity Research | NANEXA: Solid progress in development into 2023, with funding needs on the horizon Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Nanexa Nanexa publishes interim report for January – March 2023 Rapporter Ladda ner | Visa Stäng
2023-05-04 Nanexa Nanexa publicerar delårsrapport för januari-mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-03 Nanexa Nanexa publicerar årsredovisning för 2022 Rapporter Ladda ner | Visa Stäng
2023-05-03 Nanexa Nanexa publishes annual report for 2022 Rapporter Ladda ner | Visa Stäng
2023-03-23 Nanexa NEX-22 preclinical data shows controlled release of liraglutide for one month Pressreleaser Ladda ner | Visa Stäng
2023-03-23 Nanexa Prekliniska data av NEX-22 bekräftar kontrollerad frisättning av liraglutid i en månad Pressreleaser Ladda ner | Visa Stäng
2023-02-23 Emergers Emergers: NANEXA: 90 Second Pitch with CEO David Westberg Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Redeye Redeye: Nanexa Q4 2022 - A Stronger Case Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Emergers Emergers: Equity Research | NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead Pressreleaser Ladda ner | Visa Stäng
2023-02-16 Nanexa Nanexa publishes year-end report for 2022 Rapporter Ladda ner | Visa Stäng
2023-02-16 Nanexa Nanexa publicerar bokslutskommuniké för 2022 Rapporter Ladda ner | Visa Stäng
2023-02-15 Nanexa Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport Pressreleaser Ladda ner | Visa Stäng
2023-02-15 Nanexa Invitation to presentation of Nanexa’s year-end report and Q4-report Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Nanexa Nanexa participates at the 4th annual “Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation Analyser Ladda ner | Visa Stäng
2023-02-08 Nanexa Nanexa deltar på 4th annual “Beyond Medicines’ Barriers Meeting”, arrangerat av International Myeloma Foundation Analyser Ladda ner | Visa Stäng
2022-12-23 Emergers Emergers: Equity Research | NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Inbjudan till nyhetskommentar med anledning av Nanexas nyhetssläpp den 21 december 2022 Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Invitation to commentary regarding Nanexa's press release on 21 December 2022 Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk Analyser Ladda ner | Visa Stäng
2022-12-21 Nanexa Nanexa tecknar ett exklusivitets- och utvärderingsavtal värt 46,1 MSEK och genomför en riktad emission till Novo Nordisk om 17,2 MSEK Analyser Ladda ner | Visa Stäng
2022-12-06 Nanexa Nanexa har startat Fas 1-studien med NEX-20 enligt plan Analyser Ladda ner | Visa Stäng
2022-12-06 Nanexa Nanexa has started the Phase 1 study of NEX-20 according to plan Analyser Ladda ner | Visa Stäng
2022-11-16 Nanexa Nanexa AB och VitriVax, Inc. har nått en lösning på patentintrångsprocessen Analyser Ladda ner | Visa Stäng
2022-11-16 Nanexa Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit Analyser Ladda ner | Visa Stäng
2022-11-14 Nanexa Nanexa receives approval to start clinical trial with NEX-20 Analyser Ladda ner | Visa Stäng
2022-11-14 Nanexa Nanexa erhåller godkännande att starta klinisk studie med NEX-20 Analyser Ladda ner | Visa Stäng
2022-11-10 Nanexa Valberedning inför Nanexa AB (publ) årsstämma 2023 Analyser Ladda ner | Visa Stäng
2022-11-10 Nanexa Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023 Analyser Ladda ner | Visa Stäng
Analyser | 10 Nov 2022 | Nanexa

Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023

The Nomination Committee has been appointed in Nanexa AB (publ) for the Annual General Meeting 2023 in accordance with the principles adopted by Nanexa’s Annual General Meeting on 9 June 2022.

The members of the Nomination Committee are appointed by the three largest shareholders in the company by votes as of 30 September 2022. In the event that one of the three largest shareholders does not wish to appoint a member, the fourth largest shareholder shall be asked and so on until the Nomination Committee consists of three members. The Chairman of the Board of Directors shall be adjunct member of the Nomination Committee.

For 2023, there have been no changes in the proposals for members, and the members of the Nomination Committee are therefore:

  • Philip Norin
  • Hanno Lindroth, appointed by Mårten Rooth
  • Christian Östberg, appointed by Anders Johansson
  • Göran Ando, Chairman of the Board, adjunct

The Nomination Committee’s proposals are presented in the notice of the 2023 Annual General Meeting and on the company’s website, www.nanexa.com .

Shareholders may contact the Nomination Committee with suggestions regarding its work by sending e-mail to info@nanexa.se (heading ”Nanexa’s Nomination Committee”) or by letter to: Nanexa AB, Attn: Nanexa’s Nomination Committee, Virdings Allé 2, SE-754 50, Uppsala, Sweden. The date of the 2023 Annual General Meeting and the latest date for submitting proposals to the Nomination Committee will be announced on Nanexa’s website before the end of 2022.

2022-10-26 Emergers Emergers: Equity Research | NANEXA: Charging to enter triple clinical trials in the coming year Analyser Ladda ner | Visa Stäng
2022-10-25 Nanexa Nanexa publishes interim report for January – September 2022 Analyser Ladda ner | Visa Stäng
2022-10-25 Nanexa Nanexa publicerar delårsrapport för januari-september 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Nanexa Inbjudan till presentation av Nanexas Q3-rapport 2022 Analyser Ladda ner | Visa Stäng
2022-10-21 Nanexa Nanexa tecknar utvärderingsavtal med läkemedelsbolag specialiserat inom ögonområdet Analyser Ladda ner | Visa Stäng
2022-10-21 Nanexa Nanexa signs evaluation agreement with a Speciality Pharma company Analyser Ladda ner | Visa Stäng
2022-09-27 Nanexa Nanexa AB och Vitrivax, Inc har nått en överenskommelse i alla väsentliga delar Analyser Ladda ner | Visa Stäng
2022-09-27 Nanexa Nanexa AB and Vitrivax, Inc reach agreement in principle Analyser Ladda ner | Visa Stäng
2022-09-19 Emergers Emergers: NANEXA Equity Research Case Video Summary Analyser Ladda ner | Visa Stäng
2022-09-16 Emergers Emergers: Equity Research | NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market Analyser Ladda ner | Visa Stäng
2022-09-15 Nanexa Nanexa startar produktprojektet NEX-22 som adresserar en enorm marknad Analyser Ladda ner | Visa Stäng
2022-09-15 Nanexa Nanexa launches NEX-22 product project to address a huge market Analyser Ladda ner | Visa Stäng
2022-08-30 Nanexa Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag Analyser Ladda ner | Visa Stäng
2022-08-30 Nanexa Nanexa signs evaluation agreement with a Global Pharmaceutical Company Analyser Ladda ner | Visa Stäng
2022-08-29 Redeye Redeye: Nanexa - Our Q2 Comment Analyser Ladda ner | Visa Stäng
2022-08-26 Nanexa Nanexa publishes interim report for January – June 2022 Analyser Ladda ner | Visa Stäng
2022-08-26 Nanexa Nanexa publicerar delårsrapport för januari-juni 2022 Analyser Ladda ner | Visa Stäng
2022-08-25 Nanexa Nanexa receives extended GMP-certificate for the new pilot plant Analyser Ladda ner | Visa Stäng
2022-08-25 Nanexa Nanexa erhåller utökat GMP certifikat för den nya pilotanläggningen Analyser Ladda ner | Visa Stäng

Kommande händelser

3 May 2024 | Kvartalsrapport 2024-Q1
15 May 2024 | Årsstämma 2023
16 May 2024 | Årligutdelning
27 Aug 2024 | Kvartalsrapport 2024-Q2
7 Nov 2024 | Kvartalsrapport 2024-Q3
19 Feb 2025 | Bokslutskommuniké 2024